helicobacter test infai
infai, institut für biomedizinische analytik nmr-imaging gmbh - urea (13c) - breath tests; helicobacter infections - diagnostični agenti - helicobacter test infai se lahko uporabi za in vivo diagnostiko gastroduodenal helicobacter pylori v:odrasli;mladostnike, ki so verjetno, da so peptične razjede bolezni. helicobacter test infai za otroke, stare od tri do 11 let, se lahko uporabi za in vivo diagnostiko gastrduodenal helicobacter pylori:za vrednotenje uspeha za izkoreninjenje zdravljenje, ali pri invazivnih testov ni mogoče opraviti, ali ko so neskladne rezultate, ki izhajajo iz invazivnih testov. to zdravilo je samo za diagnostično uporabo.
pylobactell
torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - diagnostični agenti - to zdravilo je samo za diagnostično uporabo. za in vivo diagnostiko gastroduodenal helicobacter pylori (h.. pylori) okužbe.
linola urea 120 mg/g krema
dr. a. wolff - sečnina - krema - sečnina 120 mg / 1 g - sečnina
linola urea 120 mg/g krema
dr. a. wolff - sečnina - krema - sečnina 120 mg / 1 g - sečnina
onglyza
astrazeneca ab - saxagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
tienam 500 mg/500 mg prašek za raztopino za infundiranje
merck sharp & dohme, d.o.o. - cilastatin, imipenem - prašek za raztopino za infundiranje - cilastatin 500 mg / 1 viala; imipenem 500 mg / 1 viala - imipenem in cilastatin
tienam 500 mg/500 mg prašek za raztopino za infundiranje
merck sharp & dohme, d.o.o. - cilastatin, imipenem - prašek za raztopino za infundiranje - cilastatin 500 mg / 1 viala; imipenem 500 mg / 1 viala - imipenem in cilastatin